Moteur de recherche d’entreprises européennes
Financement de l’UE (5 087 507 €) : Approche innovante pour l’autogestion et le bien-être social des patients atteints de mucoviscidose en Europe : développement, validation et mise en œuvre d’un … Hor01/01/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Approche innovante pour l’autogestion et le bien-être social des patients atteints de mucoviscidose en Europe : développement, validation et mise en œuvre d’un outil télématique.
Cystic Fibrosis (CF) is a genetic disease with the higher incidence in Europe showing c.a. 5% mortality in childhood. The majority of patients suffer from lifelong pancreatic insufficiency leading to maldigestion of food and malabsorption and consequently with malnutrition and growth stunting. An accurate enzyme replacement arises as an early nutritional intervention able to provide better nutritional status and patients’ welfare from early stages avoiding complications associated to the development of the disease. By means of our innovative and portable ICT tool we will improve the socio-economic impact of the disease, promoting healthy lifestyle, intertwining patient empowerment, education and training with self-management and prevention of secondary CF-complications. The multidisciplinary and complementary approach of this co-developed integrative PROJECT guarantees the patient’s adherence to the treatment and the best outcome of the nutritional intervention mainly in childhood. The beneficiaries of the application comprise patients, care-givers, families and health professionals as well as health monitoring authorities. MyCyFAPP is tailored designed and will be clinically validated for CF self-management and monitoring becoming a competitive market product in Europe. This APP will have a key role as decision support system, boosting the growth and competitiveness of the participating SMEs in Europe which will ensure the commercial exploitation of the results, the market uptake and the MyCyFAPP distribution for the benefit of the patient.
| Associação para Investigação e Desenvolvimento da Faculdade de Medicina | 318 192 € |
| Cystic Fibrosis Europe e. V. | 108 816 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 342 220 € |
| Fundacion para La Investigacion del Hospital Universitario La Fe de La Comunidad Valenciana | 1 316 452 € |
| Imaginary Srl | 331 956 € |
| Katholieke Universiteit Leuven | 526 376 € |
| Servicio Madrileno de Salud | 130 675 € |
| Sintef AS | 77 500 € |
| Soluciones Tecnologicas para La Salud y El Bienestar SA | 94 700 € |
| Stiftelsen Sintef | 661 325 € |
| Universita Degli Studi Di Milano | 222 666 € |
| Universitat Politecnica de Valencia | 619 675 € |
| Youse GmbH | 336 956 € |
https://cordis.europa.eu/project/id/643806
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.